| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2006 | WO2006036670A1 Sulfonamide compounds |
| 04/06/2006 | WO2006036664A1 Substituted sulfonamidopropionamides and methods of use |
| 04/06/2006 | WO2006036655A2 Use of low dose chemically modified tetracyclines to reduce inflammatory mediators |
| 04/06/2006 | WO2006036634A2 Systemic administration of therapeutic amino acids and n-acetylamino acids |
| 04/06/2006 | WO2006036625A2 Encapsulated pharmaceutical agents |
| 04/06/2006 | WO2006036624A2 Lipid stabilized formulations |
| 04/06/2006 | WO2006036557A1 Delivery system for topically applied compounds |
| 04/06/2006 | WO2006036527A1 Substituted dipiperdine ccr2 antagonists |
| 04/06/2006 | WO2006036512A2 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| 04/06/2006 | WO2006036507A1 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| 04/06/2006 | WO2006036497A2 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| 04/06/2006 | WO2006036480A1 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists |
| 04/06/2006 | WO2006036395A2 Inhibitors of akt activity |
| 04/06/2006 | WO2006036394A2 Methods for making retinoids and uses thereof |
| 04/06/2006 | WO2006036266A1 Thienopyrimidines useful as aurora kinase inhibitors |
| 04/06/2006 | WO2006036131A1 A novel compound and a novel microorganism for producing the novel compound |
| 04/06/2006 | WO2006036074A1 Myostatin isoform |
| 04/06/2006 | WO2006036055A2 Method of female contraception and kit for use in such method |
| 04/06/2006 | WO2006036031A1 Fused furan derivative and use thereof |
| 04/06/2006 | WO2006036024A1 Proton pump inhibitors |
| 04/06/2006 | WO2006036015A2 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| 04/06/2006 | WO2006035998A1 Modified coffee, method of roasting coffee bean, coffee-like supplement and auxiliary food |
| 04/06/2006 | WO2006035974A1 Oligoribonucleotide |
| 04/06/2006 | WO2006035969A1 Ophthalmic composition containing xanthan gum and amino acid |
| 04/06/2006 | WO2006035967A1 Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor |
| 04/06/2006 | WO2006035960A2 Process for production of 2-chloro-4-nitroimidazole |
| 04/06/2006 | WO2006035954A1 Carbostyril compound |
| 04/06/2006 | WO2006035939A1 Immune stimulating oligonucleotide and use thereof in pharmaceutical |
| 04/06/2006 | WO2006035900A1 Coenzyme q10-containing emulsified composition |
| 04/06/2006 | WO2006035897A1 Composition inhibiting sex hormone-binding globulin |
| 04/06/2006 | WO2006035876A1 Preventive and/or therapeutic medicine for rheumatoid arthritis |
| 04/06/2006 | WO2006035821A1 Composition for oral cavity |
| 04/06/2006 | WO2006035796A1 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF |
| 04/06/2006 | WO2006035770A1 Process for synthesis of derivatives, compound library, method for making the mase, and screening method |
| 04/06/2006 | WO2006035760A1 Drug for treating skin disease |
| 04/06/2006 | WO2006035759A1 Drug for treating respiratory disease |
| 04/06/2006 | WO2006035700A1 Composition containing proanthocyanidin and sphingolipid |
| 04/06/2006 | WO2006035673A1 Novel method of protecting ischemic cardiopathy |
| 04/06/2006 | WO2006035617A1 α2 RECEPTOR BLOCKING AGENT CONTAINING INDOLE DERIVATIVE AS ACTIVE INGREDIENT AND VASODILATOR |
| 04/06/2006 | WO2006035459A1 An improved process for the production of derivatives of thiozolidinediones and their precursors |
| 04/06/2006 | WO2006035433A2 Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| 04/06/2006 | WO2006035431A2 Fatty acid modified polylysines as antimicrobial agents |
| 04/06/2006 | WO2006035418A2 Microcapsules comprising a methylxanthine and a corticosteroid |
| 04/06/2006 | WO2006035417A2 Dihydropyrimidine microcapsule - formulations |
| 04/06/2006 | WO2006035416A2 Minicapsule formulations |
| 04/06/2006 | WO2006035414A2 Carbidopa and levodopa dispersible tablets |
| 04/06/2006 | WO2006035313A1 Solid unit dosage forms of 5-ht1 agonist |
| 04/06/2006 | WO2006035308A1 Histamine-3 receptor antagonists |
| 04/06/2006 | WO2006035303A1 Muscarinic receptor antagonists |
| 04/06/2006 | WO2006035296A1 Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat |
| 04/06/2006 | WO2006035295A1 Process for the purification of lovastatin |
| 04/06/2006 | WO2006035291A1 Crystalline forms of cefdinir potassium |
| 04/06/2006 | WO2006035286A2 Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof |
| 04/06/2006 | WO2006035283A1 Oxazolidinone derivatives as antimicrobials |
| 04/06/2006 | WO2006035282A2 Muscarinic receptor antagonists |
| 04/06/2006 | WO2006035280A1 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| 04/06/2006 | WO2006035277A2 Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
| 04/06/2006 | WO2006035204A2 Combination comprising zd6474 and an imatinib |
| 04/06/2006 | WO2006035203A1 Cancer combination therapy comprising azd2171 and imatinib |
| 04/06/2006 | WO2006035142A1 Preparation of phenol-amide compounds with antioxidant properties |
| 04/06/2006 | WO2006035122A1 Strontium ranelate alpha crystalline form, method for the preparation thereof and pharmaceutical compositions containing said agent |
| 04/06/2006 | WO2006035084A1 Gene construction, vector and dna vaccine for the vaccination of aquatic animals |
| 04/06/2006 | WO2006035080A1 Method of obtaining cyclic amino acids |
| 04/06/2006 | WO2006035075A1 Use of vitamin d compounds for the prevention or treatment of chronic prostatitis |
| 04/06/2006 | WO2006035069A1 Hiv inhibiting 5-substituted pyrimidines |
| 04/06/2006 | WO2006035068A2 Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines |
| 04/06/2006 | WO2006035061A1 Hcv inhibiting bi-cyclic pyrimidines |
| 04/06/2006 | WO2006035051A1 A bacterial atp synthase binding domain |
| 04/06/2006 | WO2006034965A1 Process for the purification of ziprasidone |
| 04/06/2006 | WO2006034964A1 Process for preparing ziprasidone |
| 04/06/2006 | WO2006034872A1 Substituted 2-anilinopyrimidines as cell cycle kinase inhibitors or receptor tyrosine kinase inhibitors, production of said substances and use of the latter as medicaments |
| 04/06/2006 | WO2006034849A1 Antitumoral pharmaceutical compositions comprising a spisulosine and a cyclodextrin |
| 04/06/2006 | WO2006034833A1 Cyclic diarly ureas suitable as tyrosine kinase inhibitors |
| 04/06/2006 | WO2006034822A1 Novel substituted thiophencarboxylic acid amides, production thereof and use thereof as medicaments |
| 04/06/2006 | WO2006034804A1 Indozolone derivatives as 11b-hsd1 inhibitors |
| 04/06/2006 | WO2006034797A1 Thermodynamically stable form of bay 43-9006 tosylate |
| 04/06/2006 | WO2006034789A1 Proline derivatives |
| 04/06/2006 | WO2006034769A1 Carbonyl compounds usable as coagulation factor xa inhibitors |
| 04/06/2006 | WO2006034661A1 A method for producing oral solid dosage form and oral solid dosage form prepared thereby |
| 04/06/2006 | WO2006034567A1 Use of compositions comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions |
| 04/06/2006 | WO2006034560A2 Prevention and treatment of mycoplasma-associated diseases |
| 04/06/2006 | WO2006026747A3 Diphenylethylene compounds and uses thereof |
| 04/06/2006 | WO2006023460A3 COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| 04/06/2006 | WO2006019965A3 Dipeptidyl peptidase inhibitors |
| 04/06/2006 | WO2006018024A3 Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| 04/06/2006 | WO2006017320A9 Compositions and methods for myogenesis of fat-derived stem cells expressing telomerase and myocardin |
| 04/06/2006 | WO2006013457A3 Gad2 gene for possible treatment of nervous system disorders |
| 04/06/2006 | WO2006007384A3 Antibiotics containing borinic acid complexes and methods of use |
| 04/06/2006 | WO2006004793A3 Hetero isonipecotic modulators of vanilloid vr1 receptor |
| 04/06/2006 | WO2006001866A3 Crystalline forms of n-desmethylclozapine |
| 04/06/2006 | WO2005123755A3 Purine nucleotide derivatives |
| 04/06/2006 | WO2005120578A9 Biodegradable drug-polymer delivery system |
| 04/06/2006 | WO2005120489A3 Treatment of central nervous system disorders or injuries with d-methionine |
| 04/06/2006 | WO2005118601A3 Sulfonylethyl phosphorodiamidates for use in the treatment of cancer |
| 04/06/2006 | WO2005115412A3 Compositions and methods for modulating an immune response |
| 04/06/2006 | WO2005113554A3 Method of preparing 3-phenyl-2-[9h-purin-6-ylamino)-methyl]-3h-quinazolin-4-one and substituted and related compounds |
| 04/06/2006 | WO2005110375A8 Nutritional supplement for treatment of ocular diseases |
| 04/06/2006 | WO2005109304A3 Small molecules and a pharmacophore model for inhibition of anthrax lethal factor |
| 04/06/2006 | WO2005104711A8 Purification of progesterone receptor modulators |
| 04/06/2006 | WO2005104711A2 Purification of progesterone receptor modulators |